Elix Provides AI Drug Discovery Platform to Eisai

Elix has announced that its AI drug discovery platform, Elix Discovery™, has been adopted by Eisai Co., Ltd. The platform aims to enhance the efficiency of drug discovery by utilizing AI-driven molecular design and profile prediction. This adoption is expected to accelerate the drug discovery process by enabling the efficient design of promising drug candidate compounds.

Elix Discovery™ offers an intuitive graphical user interface that facilitates the automatic construction of optimal compound profile predictive models. It supports both Ligand-Based Drug Design (LBDD) and Structure-Based Drug Design (SBDD) methods, providing users with the flexibility to explore a wide range of approaches.

Eisai, a leading pharmaceutical company in Japan, anticipates that the integration of Elix Discovery™ will drive significant innovation in its drug discovery processes. The collaboration between Elix and Eisai is expected to leverage Elix's AI technology alongside Eisai's extensive expertise in drug discovery to create innovative new medicines.